title: miR-155 expression is associated with chemoimmunotherapy outcome and is modulated by Bruton's tyrosine kinase inhibition with Ibrutinib.
authors.affiliation: 1] Biomedical Sciences Graduate Program, College of Medicine, The Ohio State University, Columbus, OH, USA [2] Division of Hematology, Department of Internal Medicine and Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA.
authors.forename: D
authors.initials: D
authors.lastname: Guinn
authors.affiliation: Division of Hematology, Department of Internal Medicine and Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA.
authors.forename: A S
authors.initials: AS
authors.lastname: Ruppert
authors.affiliation: Division of Hematology, Department of Internal Medicine and Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA.
authors.forename: K
authors.initials: K
authors.lastname: Maddocks
authors.affiliation: Division of Hematology, Department of Internal Medicine and Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA.
authors.forename: S
authors.initials: S
authors.lastname: Jaglowski
authors.affiliation: Division of Hematology, Department of Internal Medicine and Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA.
authors.forename: A
authors.initials: A
authors.lastname: Gordon
authors.affiliation: Oncology Research and Development, GlaxoSmithKline, Philadelphia, PA, USA.
authors.forename: T S
authors.initials: TS
authors.lastname: Lin
authors.affiliation: Department of Medicine, University of Chicago, Chicago, IL, USA.
authors.forename: R
authors.initials: R
authors.lastname: Larson
authors.affiliation: Division of Hematology, Department of Internal Medicine and Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA.
authors.forename: G
authors.initials: G
authors.lastname: Marcucci
authors.affiliation: Division of Hematology, Department of Internal Medicine and Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA.
authors.forename: E
authors.initials: E
authors.lastname: Hertlein
authors.affiliation: Division of Hematology, Department of Internal Medicine and Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA.
authors.forename: J
authors.initials: J
authors.lastname: Woyach
authors.affiliation: 1] Division of Hematology, Department of Internal Medicine and Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA [2] Division of Medicinal Chemistry, College of Pharmacy, The Ohio State University, Columbus, OH, USA.
authors.forename: A J
authors.initials: AJ
authors.lastname: Johnson
authors.affiliation: 1] Division of Hematology, Department of Internal Medicine and Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA [2] Division of Medicinal Chemistry, College of Pharmacy, The Ohio State University, Columbus, OH, USA.
authors.forename: J C
authors.initials: JC
authors.lastname: Byrd
mesh_terms: D000225:Adenine / Q000031:analogs & derivatives; D000077329:Agammaglobulinaemia Tyrosine Kinase; D000074323:Alemtuzumab; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage; D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D018450:Disease Progression; D018572:Disease-Free Survival; D015973:Gene Expression Regulation, Leukemic; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D053208:Kaplan-Meier Estimate; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy* / Q000235:genetics* / Q000401:mortality; D035683:MicroRNAs / Q000378:metabolism*; D015999:Multivariate Analysis; D010880:Piperidines; D011505:Protein-Tyrosine Kinases / Q000378:metabolism*; D011720:Pyrazoles / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D000069283:Rituximab; D016896:Treatment Outcome; D014740:Vidarabine / Q000008:administration & dosage / Q000031:analogs & derivatives
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; C524942:MIRN155 microRNA, human; D035683:MicroRNAs; D010880:Piperidines; D011720:Pyrazoles; D011743:Pyrimidines; C551803:ibrutinib; D000074323:Alemtuzumab; D000069283:Rituximab; D011505:Protein-Tyrosine Kinases; D000077329:Agammaglobulinaemia Tyrosine Kinase; D014740:Vidarabine; D000225:Adenine; C024352:fludarabine